[go: up one dir, main page]

WO2010129467A8 - Compounds and methods for inhibition of renin, and indications therefor - Google Patents

Compounds and methods for inhibition of renin, and indications therefor Download PDF

Info

Publication number
WO2010129467A8
WO2010129467A8 PCT/US2010/033385 US2010033385W WO2010129467A8 WO 2010129467 A8 WO2010129467 A8 WO 2010129467A8 US 2010033385 W US2010033385 W US 2010033385W WO 2010129467 A8 WO2010129467 A8 WO 2010129467A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
renin
methods
inhibition
indications therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/033385
Other languages
French (fr)
Other versions
WO2010129467A1 (en
Inventor
Guoxian Wu
Prabha N. Ibrahim
Yong Zhou
Shumeye Mamo
Samuel J. Gillette
Yong-Liang Zhu
Jinyu Liu
Chao Zhang
Kam Zhang
Dean R. Artis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plexxikon Inc
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Priority to CA2761009A priority Critical patent/CA2761009A1/en
Priority to SG2011081015A priority patent/SG175877A1/en
Priority to MX2011011735A priority patent/MX2011011735A/en
Publication of WO2010129467A1 publication Critical patent/WO2010129467A1/en
Publication of WO2010129467A8 publication Critical patent/WO2010129467A8/en
Priority to IL216107A priority patent/IL216107A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds active as inhibitors of renin (e.g., compounds of Formula I) are described, as well as methods of using such compounds to treat diseases and conditions associated with the renin-angiotensin system. Formula (I)
PCT/US2010/033385 2009-05-04 2010-05-03 Compounds and methods for inhibition of renin, and indications therefor Ceased WO2010129467A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2761009A CA2761009A1 (en) 2009-05-04 2010-05-03 Compounds and methods for inhibition of renin, and indications therefor
SG2011081015A SG175877A1 (en) 2009-05-04 2010-05-03 Compounds and methods for inhibition of renin, and indications therefor
MX2011011735A MX2011011735A (en) 2009-05-04 2010-05-03 Compounds and methods for inhibition of renin, and indications therefor.
IL216107A IL216107A0 (en) 2009-05-04 2011-11-03 Compounds and methods for inhibition of renin, and indications therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17541709P 2009-05-04 2009-05-04
US61/175,417 2009-05-04

Publications (2)

Publication Number Publication Date
WO2010129467A1 WO2010129467A1 (en) 2010-11-11
WO2010129467A8 true WO2010129467A8 (en) 2010-12-16

Family

ID=42237224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/033385 Ceased WO2010129467A1 (en) 2009-05-04 2010-05-03 Compounds and methods for inhibition of renin, and indications therefor

Country Status (5)

Country Link
CA (1) CA2761009A1 (en)
IL (1) IL216107A0 (en)
MX (1) MX2011011735A (en)
SG (1) SG175877A1 (en)
WO (1) WO2010129467A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9487515B2 (en) 2006-11-22 2016-11-08 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CN102099036B (en) 2008-06-03 2015-05-27 英特芒尼公司 Compounds and methods for treating inflammatory and fibrotic disorders
BR112012011792A2 (en) 2009-11-18 2015-10-13 Plexxikon Inc "compounds and methods for modulating kinases, and indications thereof"
CA2784393A1 (en) 2009-12-23 2011-06-30 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
BR112012024380A2 (en) 2010-03-25 2015-09-15 Glaxosmithkline Llc chemical compounds
TWI619713B (en) 2010-04-21 2018-04-01 普雷辛肯公司 Compounds and methods for kinase regulation and their indications
JP5941069B2 (en) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Compounds and methods for kinase regulation and indications therefor
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN103917235A (en) 2011-05-17 2014-07-09 普莱希科公司 Kinase modulation and indications therefor
CN102993094B (en) * 2011-09-08 2014-07-23 中国石油大学(北京) Synthesizing method of tetrahydroquinoline derivative
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
UY34893A (en) 2012-07-10 2014-02-28 Takeda Pharmaceutical DERIVATIVES OF AZAINDOL
CA2883894C (en) 2012-09-06 2020-08-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
RS57117B1 (en) 2012-12-21 2018-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
SG11201506687RA (en) 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
JP6067181B2 (en) 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Aldosterone synthase inhibitor
RU2015149937A (en) 2013-05-30 2017-07-06 Плексксикон Инк. COMPOUNDS FOR KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION
EP3060563B1 (en) 2013-10-25 2018-05-02 Novartis AG Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
RU2696310C1 (en) 2013-12-20 2019-08-01 Астекс Терапьютикс Лимитед Bicyclic heterocyclic compounds and use thereof in therapy
WO2015106012A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP6525437B2 (en) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド Antifibrotic pyridinone
JP6832846B2 (en) 2014-09-15 2021-02-24 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Heterocyclic compounds and their uses
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MY195977A (en) 2015-09-21 2023-02-27 Plexxikon Inc Heterocyclic Compounds and uses Thereof
SG11201804711RA (en) 2015-12-07 2018-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US10160747B2 (en) 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TW201815766A (en) 2016-09-22 2018-05-01 美商普雷辛肯公司 Compounds and methods for IDO and TDO modulation, and indications therefor
CA3047580A1 (en) 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
US10577366B2 (en) 2017-03-20 2020-03-03 Plexxikon Inc. Crystalline forms of a compound that inhibits bromodomain
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
US10435404B2 (en) 2017-07-25 2019-10-08 Plexxikon Inc. Formulations of a compound modulating kinases
WO2019075243A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. Solid forms of a compound for modulating kinases
AU2018354423B2 (en) 2017-10-27 2024-11-07 Plexxikon Inc. Formulations of a compound modulating kinases
CA3094336A1 (en) 2018-03-20 2019-09-26 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
CN108752272B (en) * 2018-06-19 2021-02-19 西安交通大学 8-aminoquinoline amide derivative, preparation method, application and fluorescence analysis method thereof
EP3962903A1 (en) 2019-05-01 2022-03-09 Boehringer Ingelheim International GmbH (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
CN111053761B (en) * 2020-01-16 2022-05-03 杭州旦承医药科技有限公司 Bisphosphonic acid medicine for inhalation, preparation method thereof and application thereof in chronic obstructive pulmonary disease
CN115605460A (en) 2020-04-29 2023-01-13 普莱希科公司（Us） Synthesis of Heterocyclic Compounds
TW202339719A (en) 2021-12-14 2023-10-16 德商百靈佳殷格翰國際股份有限公司 Aldosterone synthase inhibitors for treating chronic kidney disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197959B1 (en) * 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
JP2010208947A (en) * 2007-06-29 2010-09-24 Dainippon Sumitomo Pharma Co Ltd Quinolone derivative

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487515B2 (en) 2006-11-22 2016-11-08 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor

Also Published As

Publication number Publication date
CA2761009A1 (en) 2010-11-11
MX2011011735A (en) 2011-11-29
SG175877A1 (en) 2011-12-29
IL216107A0 (en) 2012-01-31
WO2010129467A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
WO2010129467A8 (en) Compounds and methods for inhibition of renin, and indications therefor
WO2012037155A3 (en) Tyrosine kinase inhibitors
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2013134336A3 (en) Inhibition of adaptor associated kinase 1 for the treatment of pain
WO2008112199A8 (en) Method for inhibiting topoisomerase ii
MY162936A (en) Macrocycles as factor xia inhibitors
WO2011126903A3 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
WO2007092213A3 (en) Inhibitors of e1 activating enzyme
WO2011138328A3 (en) Use of inhibitory molecules for the treatment of pulmonary hypertension
UA104885C2 (en) Isothiazolyloxyphenyl amidines and use thereof as fungicides
AU2012249851A8 (en) MicroRNA compounds and methods for modulating miR-21 activity
WO2013003298A3 (en) Inhibitors of pde10
EA201200917A1 (en) PROCARAXES OF PLASMA KALLIKREIN INHIBITORS
EP2595482A4 (en) INHIBITORS OF ALDOSTERONE SYNTHASE
HK1210615A1 (en) Cystathionine-y-gamma-lyase (cse) inhibitors
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
HK1210614A1 (en) Cystathionine-υ-lyase (cse) inhibitors
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
UA111861C2 (en) Aromatic heterocyclic dihydroxy compound
WO2011119777A3 (en) Compositions and methods for treatment of neurodegenerative disease
WO2012065102A3 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
MX2012004780A (en) Akt inhibitors.
MX2011011272A (en) Processes and intermediates.
AU2011326186A8 (en) Selective glycosidase inhibitors and uses thereof
MX2013002851A (en) Inhibitors of notum pectinacetylesterase and methods of their use.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10717397

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012509872

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: CR2011-000570

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011002764

Country of ref document: CL

Ref document number: 2761009

Country of ref document: CA

Ref document number: 11150238

Country of ref document: CO

Ref document number: 001901-2011

Country of ref document: PE

Ref document number: MX/A/2011/011735

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 10717397

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1014458

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI1014458

Country of ref document: BR

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, EM LINGUA PORTUGUESA, AS FOLHAS DE RELATORIO DESCRITIVO E DESENHOS APRESENTADAS EM LINGUA ESTRANGEIRA NA PETICAO NO 020110112782 DE 03/11/2011, ADAPTADO A NORMA VIGENTE.

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI1014458

Country of ref document: BR